Related Experiment Videos
Recognition and management of hypercholesterolaemia in patients awaiting elective coronary artery bypass grafting
G Asimakopoulos1, C Barlow, R Pillai
1Department of Cardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital, UK.
Insights
Patients with ischemic heart disease awaiting surgery often have high cholesterol, with inadequate awareness and treatment. Improving cholesterol management in these individuals is crucial for better outcomes.
Area of Science:
- Cardiology
- Public Health
Background:
- Long-term simvastatin improved survival in ischemic heart disease patients with high cholesterol.
- Effective cholesterol management is vital for cardiovascular health.
Purpose of the Study:
- To assess awareness and adequacy of treatment for high cholesterol in patients awaiting coronary revascularization.
- To identify gaps in hypercholesterolemia management within this patient group.
Main Methods:
- Prospective study of 100 consecutive patients undergoing coronary artery bypass grafting.
- Patient interviews regarding history and treatment of high cholesterol.
- Fasting serum cholesterol measurements before surgery.
Main Results:
- 61% of patients had cholesterol levels >5.5 mmol/l.
- Among those with a history of high cholesterol, only 54% were on medication or diet.
- Inadequate awareness and treatment of hypercholesterolemia were observed.
Conclusions:
- A significant number of patients awaiting coronary artery bypass grafting are unaware of their cholesterol status.
- Management of hypercholesterolemia in patients undergoing revascularization needs improvement.
Abstract:
The recently published Scandinavian Simvastatin Survival Study showed that long-term treatment with simvastatin, in patients with ischaemic heart disease and serum cholesterol levels between 5.5 and 8.0 mmol/l, improved survival. The present study was conducted in order to evaluate whether patients with ischaemic heart disease awaiting coronary revascularisation are aware of their serum cholesterol levels and whether raised levels are being treated adequately. One hundred consecutive patients admitted from our waiting list for elective coronary artery bypass grafting, with or without valve replacement, were included in the study. The patients were asked whether they had a history of raised serum cholesterol and, if so, how this was being treated. Fasting serum cholesterol levels were subsequently taken in the morning before surgery. Forty-six patients gave a positive history of raised blood cholesterol levels; 25 of these were on cholesterol-lowering medication at the time of admission, 15 were on a lipid-lowering diet and six were not being treated. Thirty-one (67%) of these 46 patients had a serum cholesterol of more than 5.5 mmol/l, compared with 30 (56%) of the 54 patients without a positive history of hypercholesterolaemia, and 61% of the total 100 patients. These data suggest that an inadequate number of patients awaiting coronary artery bypass grafting are aware of their cholesterol status. The management of hypercholesterolaemia among these patients could be improved.